Heyman: the Brewers aren't likely to keep Prince Fielder

6 Comments

Thumbnail image for prince fielder hr celebration.jpgVia MLB Trade Rumors, Jon Heyman was on the MLB Network last night and opined that despite some preliminary talks, the Brewers are not likely to be able to sign Prince Fielder to an extension and that the big man will be traded before he can become a free agent after the 2011 season. Ryan Howard’s $25 million/year contract is the culprit. Fielder is younger than Howard, would expect at least that much money over a longer period and that may simply be too rich for Milwaukee.

This isn’t necessarily a controversial position, as the Brewers were suspected to be thinking more along the lines of Mark Teixeira money (his contract tops out at $22.5 million a year).  But as we all know, Heyman tends to know what’s happening with Scott Boras clients, which Prince Fielder is one, so the notion that the Brewers aren’t going to have enough money to keep Fielder may be a particularly informed bit of analysis.

It’s a bit premature to analyze Fielder’s worth on the free agent market like we all did with Howard this past week, but my gut feeling is that, yeah, he’s going to ask for and is probably worth Howard money, at least on a per annum basis. Contract length is going to be the real issue with him, and given his apparent future as a DH, you can figure that teams are going to loathe to go long with him.

The Brewers are 9-14 and aren’t playing inspired baseball.  If I’m running that team and I think that Boras is going to use Howard’s deal as a starting point, I consider unloading him this year.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.